Inclusion Criteria:

• Age >=18 years
• Karnofsky Performance Status (KPS) >=70%
• Histologic evidence of multiple myeloma, relapsed or relapsed/refractory disease for which no other approved treatment is available and clinically indicated
• Adverse Events resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to acceptable grades
• Adequate bone marrow, renal, adrenal, pancreatic and liver function
• Hemoglobin >= 8 g/dL
• Absolute neutrophil count >= 1.5 x 10^9 /L
• Platelet count >= 75 x 10^9 /L (without transfusions)
• Signed informed consent

Exclusion Criteria:

• Administration of chemotherapy, radiation, biological, immunotherapy or investigational agent within 28 days (6 weeks for nitrosourea and 12 weeks for BMT)
• Patients may be receiving steroids or bisphosphonates, but doses must be stable
• Patients must be off intrathecal therapy for at least 3 months prior to dosing
• Ongoing coagulopathies and/or taking anticoagulants
• Patients with evidence of mucosal or internal bleeding and/or platelet refractory
• Significant cardiac disease
• Patients with a prior hypersensitivity reaction of CTCAE Grade >= 3 to therapy containing propylene glycol or ethanol.
• Pregnant or breast-feeding women
• Significant bacterial, viral or fungal infection
• Any other medical conditions that would impose excessive risk to the patient